Clinical-stage biopharmaceutical company Atossa Therapeutics Inc (Nasdaq: ATOS) announced on Wednesday that The Healthcare Technology Report has recognized the company's founder, chairman, president, and chief executive officer Steven Quay, MD, PhD as one of 'The Top 50 Healthcare Technology CEOs of 2025'.

According to Atossa, Dr. Quay earned this recognition for his leadership in advancing innovative biotechnology solutions and building a high-performing, people-centered organisation. As a physician-scientist and entrepreneur, he has guided the development of (Z)-endoxifen, Atossa's lead precision-engineered endocrine therapy, across multiple Phase 2 clinical trials and throughout the full breast cancer treatment continuum.

The therapy has been optimized as a potent selective estrogen receptor modulator/degrader (SERM/D) with additional PKCβ1 inhibition, designed to provide consistent systemic exposure independent of CYP2D6 metabolism. The company is also exploring the application of (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD).